Source comparison
CJC-1295 No DAC vs DAC: Why the Distinction Defines Research Applicability
The 'no DAC' designation isn't a minor formulation detail. It fundamentally changes pharmacokinetics and, consequently, what research questions the peptide can answer. CJC-1295 with DAC (also called CJC-1295 DAC or Mod GRF 1-29 DAC) includes a maleimido-propri
This comparison does not assign a generated winner or score.
- The 'no DAC' designation isn't a minor formulation detail. It fundamentally changes pharmacokinetics and, consequently, what research questions the peptide can answer. CJC-1295 with DAC (also called CJC-1295 DAC or Mod GRF 1-29 DAC) includes a maleimido-proprionyl moiety that covalently binds to serum albumin, extending plasma half-life from 30 minutes to 6–8 days. That extended half-life produces continuous GH elevation rather than discrete pulses. Useful for anabolic research protocols but antithetical to pulse dynamics studies.
- Here's the practical difference: if your protocol measures GH secretion every 20 minutes across a 24-hour window to map ultradian rhythm, CJC-1295 DAC creates a sustained plateau that obscures individual peaks. The DAC-conjugated variant produces what endocrinologists call 'tonic' GH elevation. A steady-state background level 30–50% above baseline with minimal pulsatility. CJC-1295 no DAC, by contrast, delivers sharp amplitude spikes at the body's natural intervals, making discrete pulse events measurable and attributable to endogenous regulatory mechanisms rather than exogenous override.
- In our experience working with research-grade peptides, the DAC vs no-DAC distinction is the single most misunderstood specification in GHRH analogue procurement. Teams designing protocols around sleep architecture or fasting-induced GH secretion need the no-DAC variant. Anything else masks the variable they're measuring.